A5027339862- Pharmacovigilance and Adverse Drug Reactions
- Pharmaceutical studies and practices
- Drug-Induced Adverse Reactions
- Pharmaceutical Practices and Patient Outcomes
- Schizophrenia research and treatment
- Pharmacological Effects and Toxicity Studies
- Treatment of Major Depression
- Electroconvulsive Therapy Studies
- Pharmaceutical Economics and Policy
- Computational Drug Discovery Methods
- Platelet Disorders and Treatments
- Pharmaceutical industry and healthcare
- Bipolar Disorder and Treatment
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood Pressure and Hypertension Studies
- Systemic Lupus Erythematosus Research
- Forensic Toxicology and Drug Analysis
- Diabetes Treatment and Management
- Chronic Lymphocytic Leukemia Research
- Dementia and Cognitive Impairment Research
- Attention Deficit Hyperactivity Disorder
- Anesthesia and Sedative Agents
Inserm
2015-2025
Université Toulouse III - Paul Sabatier
2013-2025
Université de Toulouse
2016-2025
Centre Hospitalier Universitaire de Toulouse
2014-2024
Pharmacochimie et Pharmacologie pour le Développement
2012-2024
Centre d’Investigation Clinique 1436
2015-2024
Hôpital Purpan
2019-2024
Centre d'Investigation Clinique Robert Debré
2018-2024
Life Medical Control (France)
2015-2024
Pharmac
2023
<h3>Importance</h3> Some reports have raised concerns regarding a potential psychiatric worsening associated with first-time use of aripiprazole in patients already treated other antipsychotic medications. Whether use, particularly the long term, increases risk for serious events is unclear. <h3>Objective</h3> To assess whether switching to or adding treatment failure compared another drug previously exposed <h3>Design, Setting, and Participants</h3> This population-based cohort study was...
In pharmacovigilance, disproportionality analyses based on individual case safety reports are widely used to detect signals. Unfortunately, publishing lacks specific guidelines, often leading incomplete and ambiguous reporting, carries the risk of incorrect conclusions when data not placed in correct context. The REporting A Disproportionality analysis for drUg Safety signal detection using PharmacoVigilance (READUS-PV) statement was developed address this issue by promoting transparent...
Disproportionality analyses using reports of suspected adverse drug reactions are the most commonly used quantitative methods for detecting safety signals in pharmacovigilance. However, their and results generally poorly reported published articles existing guidelines do not capture specific features disproportionality analyses. We here describe development a guideline (REporting A analysis drUg Safety signal detection individual case PharmacoVigilance [READUS-PV]) reporting abstracts....
This study examined the rates of patients in United Kingdom treated with gabapentin and pregabalin for first time, these an off-label indication or a coprescription opioids benzodiazepines.
Abstract Background Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants antidepressants’ classes. objective of this study was to assess the putative association each antidepressant classes with disorders. Methods Using VigiBase®, WHO Pharmacovigilance database, disproportionality disorders’ reporting assessed among reactions related any antidepressant, from January 1967 February 2017, through...
Aims Adverse drug reactions (ADRs) are important causes of death. However, the main involved drugs relatively unknown. The present study was performed to characterise death‐related recorded in a large pharmacovigilance database during last 10 years. Methods A retrospective analysis VigiBase, World Health Organization database, investigating fatal ADRs registered between 1 January 2010 and 31 December 2019 male female patients aged ≥18 years reported by physicians. Analyses were descriptive...
More information would be required for a better understanding of the actual circumstances serotonin syndrome (SS) occurrence in routine clinical practice.The objective study was to analyze characteristics SS French pharmacovigilance reports, especially involved drugs and nature drug-drug interactions (DDIs).We performed retrospective analysis registered database between January 1, 1985 May 27, 2013. Only cases whose symptoms fulfilled Sternbach, Radomski, or Hunter diagnostic criteria were...
Abstract Objectives We aimed to investigate whether abatacept used in patients for RA was associated with an increased risk of reporting overall cancer and specific cancers, including breast, lung, lymphoma, melanoma non-melanoma skin when compared other biologic DMARDs (bDMARDs). Methods performed observational study within VigiBase, the World Health Organization’s global database individual case safety reports, from 2007 2017 compare cases reported exposed those bDMARDs. conducted...
Abstract Objective To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk cholangiocarcinoma in adults type 2 diabetes. Design Population based cohort study. Setting General practices contributing data to the UK Clinical Practice Research Datalink. Participants 154 162 newly treated antidiabetic drugs between 1 January 2007 31 March 2017, followed until 2018. Main outcome measures Use...
To assess whether abatacept as initial biological DMARD (bDMARD) in the treatment of RA, when compared with other bDMARDs, is associated an increased risk cancer overall and by specific sites (breast, lung, lymphoma, melanoma non-melanoma skin cancer).We performed a population-based cohort study among patients newly treated bDMARDs within US-based Truven MarketScan population Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used estimate hazard ratios 95% CIs...
In the stressful context of coronavirus disease 2019 (COVID-19) pandemic, some reports have raised concerns regarding psychiatric disorders with use hydroxychloroquine. this study, we reviewed all adverse effects hydroxychloroquine in COVID-19 patients, as well other indications, reported VigiBase, World Health Organization's (WHO) global database individual case safety reports. First, analyzed effects, including suicide, patients to 16 June 2020. We also performed disproportionality...
Abstract Aims While some concerns about vaccination-related pericarditis and/or myocarditis have been raised, no published data are available on with mRNA COVID-19 vaccines in the age group of adolescents, particularly 12–15 years. The objective this study was to determine whether risk reporting varied according dose vaccination, age, sex, and type adolescents between 12 17 Methods results We performed an observational reviewing all reports vaccinated recorded VigiBase®, World Health...
A significant heterogeneity prevails in antipsychotics (APs) safety monitoring recommendations. Youths are deemed more vulnerable to cardiometabolic side effects. We aimed assess age-dependent reporting of cardiac and metabolic disorders youths, relying on the WHO database (VigiBase®). VigiBase® was queried for all reports cardiac, glucose, lipid nutritional involving APs. Patients <18 years were classified as pediatric population. Disproportionality analyses relied Information Component...